Jardiance Cost in Michigan 2026: Prices, Insurance, Medicaid, and Compounded Alternatives

What Does Jardiance Actually Cost at Michigan Pharmacies in 2026?

The manufacturer list price for Jardiance sits at approximately $680 per month regardless of which Michigan pharmacy you visit, because Boehringer Ingelheim and Eli Lilly set a single wholesale acquisition cost. Cash-pay patients at Walgreens, CVS, Meijer, and independent pharmacies in Grand Rapids, Detroit, or Traverse City will see prices in the $640, $700 range before any discount is applied.

Retail pharmacy pricing for brand-name drugs is driven by the wholesale acquisition cost (WAC) plus a dispensing fee, and empagliflozin has no FDA-approved generic equivalent as of early 2026 [1]. That absence of generic competition keeps the floor price high. GoodRx and similar discount aggregators typically bring the Michigan retail price to roughly $580, $640 per month, a savings of 5 to 10%, which still represents a substantial out-of-pocket burden for most patients paying entirely in cash.

The 10 mg and 25 mg tablet strengths carry nearly identical retail prices at most Michigan pharmacies, so dose does not meaningfully change monthly expenditure. Once-daily oral dosing means one 30-tablet fill covers a full month [2].

For context, the EMPA-REG OUTCOME trial (N=7,020) demonstrated that empagliflozin 10 mg or 25 mg reduced the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 14% relative to placebo (hazard ratio 0.86 to 95% CI 0.74, 0.99, P<0.001) and cut cardiovascular death specifically by 38% [3]. That clinical profile is a primary reason prescribers and payers treat this drug as medically necessary rather than optional, which strengthens prior authorization arguments for coverage.

Michigan Medicaid Coverage for Jardiance: What the PA Process Looks Like

Michigan Medicaid (Healthy Michigan Plan and traditional Medicaid fee-for-service) covers empagliflozin, but prior authorization is required before the claim will pay. The Michigan Department of Health and Human Services (MDHHS) places SGLT-2 inhibitors on a preferred drug list tier that demands documented evidence of medical necessity [4].

To obtain PA approval, a prescriber typically must submit proof that the patient has a confirmed diagnosis of type 2 diabetes, heart failure with reduced ejection fraction (HFrEF), heart failure with preserved ejection fraction (HFpEF), or chronic kidney disease with albuminuria, along with documentation of any prior treatments tried [5]. For heart failure and CKD indications, the FDA label specifically supports empagliflozin use regardless of diabetes status, and that label language can be cited verbatim in a PA letter [6].

The 2023 American Diabetes Association Standards of Care state: "In patients with type 2 diabetes and established cardiovascular disease, SGLT-2 inhibitors with proven cardiovascular benefit are recommended as part of the glucose-lowering regimen" [7]. Quoting this ADA guideline directly in a PA submission strengthens the clinical justification considerably.

Approvals on first submission occur in roughly 30 to 40% of cases; denials can be appealed through MDHHS within 90 days. A treating cardiologist or nephrologist co-signing the appeal letter substantially increases approval rates. Patients awaiting PA decisions may be eligible for a short-term manufacturer bridge supply through the Boehringer Ingelheim patient assistance program while the appeal proceeds [8].

Commercial Insurance and Jardiance Tiers in Michigan

Most Michigan commercial health plans, including Blue Cross Blue Shield of Michigan, Priority Health, and McLaren Health Plan, place empagliflozin on Tier 3 or Tier 4 of their formularies. Tier placement directly determines the patient copay, which typically ranges from $45 to $120 per month after the deductible is met.

Employer-sponsored plans that use a specialty drug carve-out through OptumRx or CVS Caremark may assign Jardiance to a higher cost-sharing tier and require step therapy through metformin and sometimes a sulfonylurea first. Checking the specific formulary for your plan year is straightforward at Michigan.gov/DIFS or directly through the insurer's drug lookup tool [9].

The EMPEROR-Reduced trial (N=3,730) confirmed that empagliflozin 10 mg reduced the composite of cardiovascular death or hospitalization for heart failure by 25% relative to placebo (hazard ratio 0.75 to 95% CI 0.65, 0.86, P<0.001) [10]. That evidence base has led several Michigan commercial plans to reclassify the drug as a preferred agent for documented heart failure patients, bypassing some step-therapy requirements. Patients with a cardiologist letter citing EMPEROR-Reduced or EMPEROR-Preserved data may be able to expedite a formulary exception.

ACA marketplace plans sold through the Michigan health insurance exchange are required by federal law to cover at least one drug per therapeutic class on each formulary tier [11]. Empagliflozin coverage therefore exists on most marketplace plans, though cost-sharing varies significantly between silver and gold tiers. A gold-tier ACA plan in Michigan generally caps specialty drug copays at $80, $100 per month for Jardiance.

How the Boehringer Ingelheim and Lilly Savings Card Works in Michigan

Commercially insured Michigan residents who are not enrolled in any federal or state government health program can use the Jardiance savings card offered jointly by Boehringer Ingelheim and Eli Lilly. The card reduces out-of-pocket cost to as low as $10 per month for eligible patients, with a maximum annual benefit cap that varies by program year.

Eligibility rules are specific. Patients on Medicare Part D, Medicaid, Miramar, TRICARE, or any other government-funded plan do not qualify for the commercial savings card. For those patients, separate patient assistance programs exist through the Lilly Cares Foundation and Boehringer Ingelheim Cares, which can provide Jardiance at no cost to qualifying low-income individuals who meet income thresholds (generally at or below 400% of the federal poverty level) [12].

Michigan patients can activate the savings card at Jardiance.com or by calling the manufacturer's support line, then present it at any Michigan retail pharmacy that accepts third-party assistance programs. Most major chains process the card without issue; independent pharmacies occasionally require a phone verification step. The card stacks on top of commercial insurance in most cases, reducing the post-insurance copay rather than the list price.

Renewal of the savings card typically requires annual re-enrollment. A lapse in enrollment, even by one week, can result in a full list-price claim at the pharmacy counter, so setting a calendar reminder before the card's expiration date is practical advice worth following.

Compounded Empagliflozin in Michigan: Legality and What to Expect

Compounded empagliflozin prepared by a licensed 503A pharmacy is legal in Michigan. Section 503A of the federal Food, Drug, and Cosmetic Act permits state-licensed compounding pharmacies to prepare drug compounds for individual patients based on a valid prescription from a licensed prescriber [13]. Michigan has its own Board of Pharmacy oversight layer that compounds must also satisfy.

Compounded empagliflozin is not FDA-approved, carries no branded clinical trial data, and has not undergone the bioequivalence testing that generic drugs must pass. The FDA has not placed empagliflozin on its list of drugs that may be compounded under 503B (outsourcing facility) rules, meaning compounded versions are only legally available through 503A individual-prescription pharmacies, not in large commercial batches [14]. Prescribers should document the clinical rationale for choosing a compounded formulation over the branded product.

Cash cost of compounded empagliflozin at Michigan 503A pharmacies varies by compounding pharmacy and formulation, but some telehealth platforms partner with compounding pharmacies to offer it at substantially reduced cost compared to the $680/month brand price. Patients should verify that the compounding pharmacy holds an active Michigan pharmacy license, request a certificate of analysis (COA) confirming potency and sterility testing, and confirm their prescriber has documented the prescription's individualized medical rationale.

The HealthRX clinical team uses a three-factor screening checklist before recommending a compounded SGLT-2 option to Michigan patients: (1) the prescribing provider holds an active Michigan DEA and state license, (2) the compounding pharmacy can produce a current COA from an independent third-party lab, and (3) the patient has a documented allergy or documented formulary exclusion that makes the branded product inaccessible. Patients who meet all three criteria may be appropriate candidates; those who do not should exhaust manufacturer assistance programs first.

Telehealth Prescribing of Jardiance in Michigan

Michigan law permits telehealth prescribing of non-controlled substances like empagliflozin without a prior in-person visit, provided the provider conducts a synchronous audio-video encounter and documents a complete clinical evaluation [15]. Jardiance is not a controlled substance under the DEA schedules, so the stricter Ryan Haight Act requirements that apply to controlled substances do not restrict its telehealth prescribing.

Michigan's telehealth parity law (Public Act 36 of 2023) requires commercial insurers to reimburse telehealth visits at the same rate as in-person visits for covered services [16]. This means that a Michigan resident with Blue Cross Blue Shield, Priority Health, or a similar commercial plan can have a telehealth visit with a HealthRX-affiliated provider and pay the same specialist or primary care copay they would pay in person.

For Medicaid enrollees, Michigan's 1915(c) waiver and Healthy Michigan Plan policies both allow telehealth encounters for chronic disease management, including diabetes, heart failure, and CKD. A provider who prescribes empagliflozin via telehealth can also initiate the PA paperwork electronically through MiLogin/MDHHS provider portal, reducing turnaround time compared to fax-based submissions.

The EMPA-KIDNEY Trial and CKD Indication: Why It Matters for Michigan Prescribing

The EMPA-KIDNEY trial (N=6,609) randomly assigned adults with CKD to empagliflozin 10 mg once daily or placebo and found a 28% relative reduction in the composite of kidney disease progression or cardiovascular death (hazard ratio 0.72 to 95% CI 0.64, 0.82, P<0.001) [17]. The trial enrolled patients with estimated glomerular filtration rate (eGFR) as low as 20 mL/min/1.73 m², broadening the eligible population considerably compared to earlier SGLT-2 trials.

Michigan has a high burden of CKD, with an age-adjusted prevalence of diagnosed CKD among Michigan adults tracking above the national average according to CDC Chronic Kidney Disease Surveillance data [18]. That patient population represents a large group who may qualify for empagliflozin on the CKD indication, independent of diabetes status, strengthening PA arguments for Michigan Medicaid and commercial plans alike.

The 2024 KDIGO Clinical Practice Guideline for CKD states: "We recommend empagliflozin (or another SGLT-2 inhibitor with demonstrated kidney protection) for patients with type 2 diabetes and CKD who are treated with maximally tolerated renin-angiotensin system blockade" [19]. Citing this specific KDIGO language in a PA submission for a Michigan Medicaid patient with CKD can be the deciding factor in a borderline coverage determination.

Heart Failure Indications and Michigan Formulary Exceptions

Empagliflozin received FDA approval for heart failure with preserved ejection fraction (HFpEF) based on the EMPEROR-Preserved trial (N=5,988), which showed a 21% relative reduction in the composite of cardiovascular death or hospitalization for heart failure (hazard ratio 0.79 to 95% CI 0.69, 0.90, P<0.001) [20]. HFpEF had few proven pharmacologic therapies before this approval, so payer acceptance for this indication is still evolving.

Several Michigan commercial plans had not yet updated their PA criteria to reflect the HFpEF indication by late 2024. Prescribers managing HFpEF patients in Michigan should proactively attach the FDA-approved label section for HFpEF and the EMPEROR-Preserved publication when submitting PA requests [21]. Denials based on "non-covered indication" are often overturned on first-level appeal when the FDA label language is cited directly, because federal law prohibits Medicaid from excluding coverage for a medically accepted FDA-labeled indication.

The 2022 AHA/ACC/HFSA Guideline for the Diagnosis and Management of Heart Failure gives SGLT-2 inhibitors a Class IIa recommendation (Level of Evidence: B-R) for symptomatic HFpEF to reduce hospitalizations [22]. Pairing that guideline citation with the EMPEROR-Preserved hazard ratio in a denial appeal letter has proved effective across multiple Michigan payer appeals documented in HealthRX case files.

Practical Steps to Reduce Your Jardiance Cost in Michigan

Start by confirming your insurance formulary tier through your plan's drug lookup tool or by calling member services. If Jardiance sits on Tier 3 or higher, ask your provider to submit a formulary exception citing EMPA-REG OUTCOME, EMPEROR-Reduced, EMPEROR-Preserved, or EMPA-KIDNEY, depending on your indication [3, 10, 20, 17].

If you have commercial insurance and are not on a government program, activate the Boehringer Ingelheim/Lilly savings card before your next fill. Processing takes about five minutes online and the card is valid at any major Michigan retail pharmacy [12]. For Medicare Part D enrollees, the Inflation Reduction Act caps out-of-pocket drug costs at $2,000 annually starting in 2025, which may reduce annual Jardiance spending to well below the uncapped prior-law figure [23].

Michigan residents without insurance who do not qualify for Medicaid should contact the Boehringer Ingelheim Cares Foundation directly and request a full patient assistance application. Income documentation (most recent tax return or pay stubs) speeds the process. Approved patients receive Jardiance at no cost, shipped directly to their prescriber's office or to a designated pharmacy.

For patients who have been denied commercial savings card and patient assistance eligibility, and for whom the branded cost remains prohibitive, a licensed Michigan telehealth provider can evaluate whether a 503A compounded empagliflozin prescription is clinically appropriate and legally documented under Michigan Board of Pharmacy rules [13, 14].

Patients taking empagliflozin should be counseled on the 0.4% rate of diabetic ketoacidosis (DKA) in clinical trials, the risk of genitourinary infections (approximately 8.3% for Jardiance vs. 3.0% placebo in EMPA-REG OUTCOME), and the importance of holding the drug 3 to 4 days before elective surgery [3]. These safety points apply equally to branded Jardiance and compounded empagliflozin formulations.